Evidence map›Paper›PMID 40396270›Full record

ArticleJournal of biomedical research2025

1-year outcomes of single bolus r-SAK before primary PCI for STEMI: The follow-up of OPTIMA-5.

Chen Li, Jie Yu, Tian Wu, Qingxia Lin, Rui Hua, Zihang Zhong, Yule Li, Kun Liu, Li Zhu, Naiquan Yang and 21 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of biomedical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Chen LiDepartment of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China.
Jie YuDepartment of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China.
Tian WuDepartment of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China.
Qingxia LinDepartment of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China.
Rui HuaDepartment of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China.
Zihang ZhongDepartment of Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 211166, China.
Yule LiCollege of Letters and Science, University of Wisconsin-Madison, Madison, WI 53715-1007, USA.
Kun LiuDepartment of Cardiology, the First People's Hospital of Lianyungang, Lianyungang, Jiangsu 222002, China.
Li ZhuDepartment of Cardiology, Taizhou People's Hospital, Taizhou, Jiangsu 225300, China.
Naiquan YangDepartment of Cardiology, Huai'an Second People's Hospital Affiliated to Xuzhou Medical University, Huai'an, Jiangsu 223200, China.
Xin ChenDepartment of Cardiology, the Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University, Changzhou, Jiangsu 213164, China.
Xiaoyan WangDepartment of Cardiology, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu 214000, China.
Xin ZhaoDepartment of Cardiology, the Second Hospital of Dalian Medical University, Dalian, Liaoning 116027, China.
Jun JiangDepartment of Cardiology, the Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, China.
Bo ZhaoDepartment of Cardiology, the First People's Hospital of Lianyungang, Lianyungang, Jiangsu 222002, China.
Xiwen ZhangDepartment of Cardiology, the Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu 223300, China.
Pengsheng ChenDepartment of Cardiology, Xuzhou Central Hospital, Xuzhou, Jiangsu 221000, China.
Tong WangDepartment of Cardiology, Yancheng No.1 People's Hospital, Yancheng, Jiangsu 224000, China.
Yi XuDepartment of Radiology, the First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu 210029, China.
Gaoyong LiaoXintrum Pharmaceuticals Co., Ltd., Nanjing, Jiangsu 211100, China.
Liang YuanDepartment of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China.
Bo ChenDepartment of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China.
Zhihui XuDepartment of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China.
Xiaoxuan GongDepartment of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China.
Wenhao ZhangDepartment of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China.
Chunyue TanDepartment of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China.
Lei XuDepartment of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China.
Qiang HuangDepartment of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China.
Jianling BaiDepartment of Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 211166, China.
John W EikelboomDepartment of Medicine, McMaster University or Thrombosis Service, Hamilton General Hospital, Hamilton Ontario L8S 4L8, Canada.
Chunjian LiDepartment of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The OPTIMA-5 study demonstrated that a single bolus of half-dose recombinant staphylokinase (r-SAK) before primary percutaneous coronary intervention (PCI) significantly improved the patency of infarct related artery in patients with ST-elevation myocardial infarction (STEMI) expected to undergo PCI within 120 minutes. This study aimed to investigate the 1-year clinical outcome and the effect of the r-SAK antibody on a second r-SAK thrombolysis in OPTIMA-5 patients. The clinical outcome was major adverse cardiovascular events (MACE) within 360 days. Patients' r-SAK antibodies were determined on days 90 ± 7, 180 ± 7, and 360 ± 14 after thrombolysis, and

Indexed as

myocardial infarctionpercutaneous coronary intervention (PCI)recombinant staphylokinase (r-SAK)thrombolysis

Identifiers

PMID40396270
PMCPMC12683507

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.